Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Date: November 18, 2015
Pages: 60
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: K22938E6CAFEN
Leaflet:

Download PDF Leaflet

Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Kissei Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kissei Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Kissei Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Kissei Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Kissei Pharmaceutical Co., Ltd.’s pipeline products
Reasons to buy
  • Evaluate Kissei Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Kissei Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Kissei Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Kissei Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kissei Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Kissei Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Kissei Pharmaceutical Co., Ltd. Snapshot
Kissei Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Kissei Pharmaceutical Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Kissei Pharmaceutical Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Kissei Pharmaceutical Co., Ltd. - Pipeline Products Glance
Kissei Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Kissei Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Kissei Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Kissei Pharmaceutical Co., Ltd. - Drug Profiles
mitiglinide
Product Description
Mechanism of Action
R&D Progress
ozagrel
Product Description
Mechanism of Action
R&D Progress
rovatirelin
Product Description
Mechanism of Action
R&D Progress
(remogliflozin etabonate + metformin hydrochloride)
Product Description
Mechanism of Action
R&D Progress
bedoradrine sulfate
Product Description
Mechanism of Action
R&D Progress
KLH-2109
Product Description
Mechanism of Action
R&D Progress
KWA-0711
Product Description
Mechanism of Action
R&D Progress
remogliflozin etabonate
Product Description
Mechanism of Action
R&D Progress
YS-110
Product Description
Mechanism of Action
R&D Progress
AS-192426900
Product Description
Mechanism of Action
R&D Progress
AS-192781900
Product Description
Mechanism of Action
R&D Progress
AS-193280400
Product Description
Mechanism of Action
R&D Progress
KDT-3594
Product Description
Mechanism of Action
R&D Progress
KGO-2142
Product Description
Mechanism of Action
R&D Progress
KGO-2173
Product Description
Mechanism of Action
R&D Progress
KOM-1962
Product Description
Mechanism of Action
R&D Progress
KTA-439
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia
Product Description
Mechanism of Action
R&D Progress
KTA-574
Product Description
Mechanism of Action
R&D Progress
Kissei Pharmaceutical Co., Ltd. - Pipeline Analysis
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Target
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
Kissei Pharmaceutical Co., Ltd. - Recent Pipeline Updates
Kissei Pharmaceutical Co., Ltd. - Dormant Projects
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
diquafosol tetrasodium
KGA-3235
KLS-0611
KUX-1151
remogliflozin etabonate
Kissei Pharmaceutical Co., Ltd. - Company Statement
Kissei Pharmaceutical Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Kissei Pharmaceutical Co., Ltd., Key Information
Kissei Pharmaceutical Co., Ltd., Key Facts
Kissei Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
Kissei Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
Kissei Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Kissei Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
Kissei Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Kissei Pharmaceutical Co., Ltd. - Pre-Registration, 2015
Kissei Pharmaceutical Co., Ltd. - Phase III, 2015
Kissei Pharmaceutical Co., Ltd. - Phase II, 2015
Kissei Pharmaceutical Co., Ltd. - Phase I, 2015
Kissei Pharmaceutical Co., Ltd. - Preclinical, 2015
Kissei Pharmaceutical Co., Ltd. - Discovery, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
Kissei Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2015
Kissei Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2015
Kissei Pharmaceutical Co., Ltd., Other Locations
Kissei Pharmaceutical Co., Ltd., Subsidiaries

LIST OF FIGURES

Kissei Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
Kissei Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
Kissei Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: